Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MERTK positive |
| Therapy | Methotrexate + UNC2025 |
| Indication/Tumor Type | acute lymphoblastic leukemia |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MERTK positive | acute lymphoblastic leukemia | sensitive | Methotrexate + UNC2025 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, combination of UNC2025 and Methotrexate resulted in improved tumor suppression and survival compared to single agent treatment in cell line xenograft models of acute lymphocytic leukemia (PMID: 27649555). | 27649555 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27649555) | UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. | Full reference... |